Epigenetic changes at gene promoters in response to immune activation in utero

Brain, Behavior, and Immunity

Volumn 30, Issue , 2013, Pages 168-175

  Tang, Bin ^a   Jia, Haiqun ^a   Kast, Ryan J ^a   Thomas, Elizabeth A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Gene expression; Glutamate; Histone; Immune; Neurodevelopment; Psychiatric; Schizophrenia

Indexed keywords

BRAIN PROTEIN; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; GLUTAMATE RECEPTOR; GRIA1 PROTEIN; HISTONE H3; HISTONE H4; LYSINE; NTRK3 PROTEIN; POLYINOSINIC POLYCYTIDYLIC ACID; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; EPIGENETICS; GENE EXPRESSION; GENETIC ASSOCIATION; HIPPOCAMPUS; HISTONE ACETYLATION; IMMUNE RESPONSE; MOUSE; NERVE CELL DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROMOTER REGION; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ANIMALS; BEHAVIOR, ANIMAL; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; MALE; MICE; POLY I-C; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROMOTER REGIONS, GENETIC; SCHIZOPHRENIA;

EID: 84876885338     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2013.01.086     Document Type: Article

References (59)

1. Akbarian S., Huang H.S. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res. Rev. 2006, 52:293-304.
2. Bale T.L., Baram T.Z., Brown A.S., Goldstein J.M., et al. Early life programming and neurodevelopmental disorders. Biol. Psychiatry 2010, 68:314-319.
3. Braconi C., Huang N., Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010, 51:881-890.
4. Connor C.M., Dincer A., Straubhaar J., Galler J.R., et al. Maternal immune activation alters behavior in adult offspring, with subtle changes in the cortical transcriptome and epigenome. Schizophr. Res. 2012, 140:175-184.
5. D'Anello L., Sansone P., Storci G., Mitrugno V., et al. Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol. Cancer 2011, 9:300.
6. Desplats P.A., Kass K.E., Gilmartin T., Stanwood G.D., et al. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J. Neurochem. 2006, 96:743-757.
7. Ernst J., Kellis M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat. Biotechnol. 2011, 28:817-825.
8. Foran E., Garrity-Park M.M., Mureau C., Newell J., et al. Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6. Mol. Cancer Res. 2010, 8:471-481.
9. Franklin T.B., Mansuy I.M. Epigenetic inheritance in mammals: evidence for the impact of adverse environmental effects. Neurobiol. Dis. 2010, 39:61-65.
10. Garay P.A., Hsiao E.Y., Patterson P.H., McAllister A.K. Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development. Brain Behav. Immun. 2012, (Epub ahead of print).
11. Garbett K.A., Hsiao E.Y., Kalman S., Patterson P.H., et al. Effects of maternal immune activation on gene expression patterns in the fetal brain. Transl. Psychiatry 2012, 2:e98.
12. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001, 156:117-154.
13. Giegling I., Hartmann A.M., Genius J., Benninghoff J., et al. Systems biology and complex neurobehavioral traits. Pharmacopsychiatry 2008, 41(Suppl. 1):S32-S36.
14. Gonda Y., Andrews W.D., Tabata H., Namba T., et al. Robo1 regulates the migration and laminar distribution of upper-layer pyramidal neurons of the cerebral cortex. Cereb. Cortex 2012, (Epub ahead of print).
15. Harvey L., Boksa P. A stereological comparison of GAD67 and reelin expression in the hippocampal stratum oriens of offspring from two mouse models of maternal inflammation during pregnancy. Neuropharmacology 2012, 62:1767-1776.
16. Hashimoto T., Bergen S.E., Nguyen Q.L., Xu B., et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J. Neurosci. 2005, 25:372-383.
17. Heintzman N.D., Hon G.C., Hawkins R.D., Kheradpour P., et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009, 459:108-112.
18. Hodge D.R., Peng B., Cherry J.C., Hurt E.M., et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res. 2005, 65:4673-4682.
19. Hodge D.R., Xiao W., Clausen P.A., Heidecker G., et al. Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. J. Biol. Chem. 2001, 276:39508-39511.
20. Horvath, S., Janka, Z., Mirnics, K., 2011. Analyzing schizophrenia by DNA microarrays. Biol. Psychiatry 69, 157-62.
21. Hsiao E.Y., Patterson P.H. Activation of the maternal immune system induces endocrine changes in the placenta via IL-6. Brain Behav. Immun. 2011, 25:604-615.
22. Ibi D., Nagai T., Kitahara Y., Mizoguchi H., et al. Neonatal polyI:C treatment in mice results in schizophrenia-like behavioral and neurochemical abnormalities in adulthood. Neurosci. Res. 2009, 64:297-305.
23. Ito H.T., Smith S.E., Hsiao E., Patterson P.H. Maternal immune activation alters nonspatial information processing in the hippocampus of the adult offspring. Brain Behav. Immun. 2010, 24:930-941.
24. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry 2004, 9(984-997):79.
25. Lin C.H., Lane H.Y., Tsai G.E. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol. Biochem. Behav. 2011, 100:665-677.
26. Luo R.X., Postigo A.A., Dean D.C. Rb interacts with histone deacetylase to repress transcription. Cell 1998, 92:463-473.
27. Malkova N.V., Yu C.Z., Hsiao E.Y., Moore M.J., et al. Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav. Immun. 2012, 26:607-616.
28. Meyer U., Feldon J. Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology 2009, 206:587-602.
29. Meyer U., Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog. Neurobiol. 2010, 90:285-326.
30. Meyer U., Feldon J. To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models. Neuropharmacology 2012, 62:1308-1321.
31. Meyer U., Feldon J., Fatemi S.H. In-vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders. Neurosci. Biobehav. Rev. 2009, 33:1061-1079.
32. Meyer U., Murray P.J., Urwyler A., Yee B.K., et al. Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling. Mol. Psychiatry 2008, 13:208-221.
33. Meyer U., Nyffeler M., Engler A., Urwyler A., et al. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J. Neurosci. 2006, 26:4752-4762.
34. Mirnics K., Levitt P., Lewis D.A. Critical appraisal of DNA microarrays in psychiatric genomics. Biol. Psychiatry 2006, 60:163-176.
35. Moghaddam B., Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2011, 37:4-15.
36. Narayan S., Tang B., Head S.R., Gilmartin T.J., et al. Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res. 2008, 1239:235-248.
37. Oh-Nishi A., Obayashi S., Sugihara I., Minamimoto T., et al. Maternal immune activation by polyriboinosinic-polyribocytidilic acid injection produces synaptic dysfunction but not neuronal loss in the hippocampus of juvenile rat offspring. Brain Res. 2010, 1363:170-179.
38. Otnaess M.K., Djurovic S., Rimol L.M., Kulle B., et al. Evidence for a possible association of neurotrophin receptor (NTRK-3) gene polymorphisms with hippocampal function and schizophrenia. Neurobiol. Dis. 2009, 34:518-524.
39. Patterson P.H. Maternal infection and immune involvement in autism. Trends Mol. Med. 2011, 17:389-394.
40. Paul-Samojedny M., Kowalczyk M., Suchanek R., Owczarek A., et al. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia-a case-control study. J. Mol. Neurosci. 2010, 42:112-119.
41. Ponimaskin E., Voyno-Yasenetskaya T., Richter D.W., Schachner M., et al. Morphogenic signaling in neurons via neurotransmitter receptors and small GTPases. Mol. Neurobiol. 2007, 35:278-287.
42. Potkin S.G., Macciardi F., Guffanti G., Fallon J.H., et al. Identifying gene regulatory networks in schizophrenia. Neuroimage 2010, 53:839-847.
43. Potkin S.G., Turner J.A., Fallon J.A., Lakatos A., et al. Gene discovery through imaging genetics: identification of two novel genes associated with schizophrenia. Mol. Psychiatry 2009, 14:416-428.
44. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry 2005, 10:434-449.
45. Riley B., Kendler K.S. Molecular genetic studies of schizophrenia. Eur. J. Hum. Genet. 2006, 14:669-680.
46. Ross C.A., Margolis R.L., Reading S.A., Pletnikov M., et al. Neurobiology of schizophrenia. Neuron 2006, 52:139-153.
47. Samuelsson A.M., Alexanderson C., Molne J., Haraldsson B., et al. Prenatal exposure to interleukin-6 results in hypertension and alterations in the renin-angiotensin system of the rat. J. Physiol. 2006, 575:855-867.
48. Seeman P. Glutamate and dopamine components in schizophrenia. J. Psychiatry Neurosci. 2009, 34:143-149.
49. Smith S.E., Li J., Garbett K., Mirnics K., et al. Maternal immune activation alters fetal brain development through interleukin-6. J. Neurosci. 2007, 27:10695-10702.
50. Soumiya H., Fukumitsu H., Furukawa S. Prenatal immune challenge compromises development of upper-layer but not deeper-layer neurons of the mouse cerebral cortex. J. Neurosci. Res. 2011, 89:1342-1350.
51. Tang B., Dean B., Thomas E.A. Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders. Transl. Psychiatry 2011, 1:e64.
52. Thaler R., Agsten M., Spitzer S., Paschalis E.P., et al. Homocysteine suppresses the expression of the collagen cross-linker lysyl oxidase involving IL-6, Fli1, and epigenetic DNA methylation. J. Biol. Chem. 2011, 286:5578-5588.
53. Thomas E.A., Coppola G., Desplats P.A., Tang B., et al. The HDAC Inhibitor, 4b, ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. USA 2008, 105:15564-15569.
54. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr. Bull. 2010, 36:246-270.
55. Wehbe H., Henson R., Meng F., Mize-Berge J., et al. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 2006, 66:10517-10524.
56. Weickert C.S., Ligons D.L., Romanczyk T., Ungaro G., et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol. Psychiatry 2005, 10:637-650.
57. Wolf S.A., Melnik A., Kempermann G. Physical exercise increases adult neurogenesis and telomerase activity, and improves behavioral deficits in a mouse model of schizophrenia. Brain Behav. Immun. 2010, 25:971-980.
58. Yamaguchi H., Zhou C., Lin S.C., Durand B., et al. The nuclear orphan receptor COUP-TFI is important for differentiation of oligodendrocytes. Dev. Biol. 2004, 266:238-251.
59. Zuckerman L., Weiner I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J. Psychiatr. Res. 2005, 39:311-323.